Takeda Hit with $885M US Antitrust Verdict Over Amitiza Generic Delay

Event Summary

On May 18, a U.S. jury found Takeda Pharmaceutical liable for approximately $885 million in damages for delaying a generic version of its drug Amitiza. This ruling is part of an antitrust case focusing on Takeda's market practices.